BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  04:00 2022-07-06 pm EDT
246.28 USD   -0.67%
09:05aBecton, Dickinson - BD Names Rishi Grover as Chief Integrated Supply Chain Officer
AQ
09:05aBecton, Dickinson - BD Issues 2021 ESG Report
AQ
07/05Becton Dickinson Appoints Rishi Grover as Chief Integrated Supply Chain Officer
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Becton, Dickinson and Company Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S

05/12/2022 | 06:50am EDT

Becton, Dickinson and Company announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform. With 510(k) clearance from the U.S. Food and Drug Administration (FDA), the new BD COR™ MX instrument is a new analytic instrument option for the BD COR™ System. The first test available on the new system is the BD CTGCTV2 molecular assay, a single test that detects the three most prevalent non-viral sexually transmitted infections (STIs) — Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and Trichomonas vaginalis (TV). These three STIs can include a range of negative patient outcomes, from pregnancy complications to increased risk of HIV. The BD COR™ MX/PX System integrates and automates the complete molecular laboratory workflow, from sample processing to diagnostic test result for large, high-throughput labs. The BD COR™ System eliminates the need to sort specimens enabling the lab tech to have very little interaction with the specimen freeing up time for other critical lab processes. Together, the BD COR™ MX/PX System allows 1,700 specimens to be loaded, with onboard capacity for reagents and samples that provide more than seven hours of unimpeded system processing. The system is capable of delivering up to 1,000 sample results in 24 hours, eliminating multiple manual interactions per shift that were traditionally required. It also offers dual DNA targets for CT and GC detection together in the same sample and assay, which can help reduce false positives. The BD COR™ System also includes a GX instrument, which leverages the BD Onclarity™ HPV Assay with extended genotyping to screen for HPV infections. The GX instrument coupled with the availability in the U.S. of the MX instrument, which was CE marked in 2021, expands the use of the platform and automates testing for a growing list of high-demand, essential assays for women's health and STI testing. Additional assays for the MX instrument are in development and are planned beyond women's health and STI testing. The BD COR™ System is fully automated, modular, and scalable instrument, designed to address multiple needs within laboratories to handle expanding molecular testing volumes. The BD COR™ System is particularly well-suited for laboratories requiring high throughput testing because of innovative automation, minimizing staff interaction by maximizing laboratory workflow efficiencies.


© S&P Capital IQ 2022
All news about BECTON, DICKINSON AND COMPANY
09:05aBecton, Dickinson - BD Names Rishi Grover as Chief Integrated Supply Chain Officer
AQ
09:05aBecton, Dickinson - BD Issues 2021 ESG Report
AQ
07/05Becton Dickinson Appoints Rishi Grover as Chief Integrated Supply Chain Officer
MT
07/05BD Names Rishi Grover as Chief Integrated Supply Chain Officer
PR
07/05Becton, Dickinson and Company Announces Management Changes
CI
07/05Evercore ISI Adjusts Price Target on Becton Dickinson and Co. to $265 From $300, Keeps ..
MT
07/05BD Issues 2021 ESG Report
PR
06/30Becton, Dickinson Unveils Combination Assay for COVID-19, Other Respiratory Viruses
MT
06/30BD Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Viru..
PR
06/30Becton, Dickinson and Company Launches Combination Test for COVID-19, Influenza A/B and..
CI
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 18 674 M - -
Net income 2022 1 770 M - -
Net Debt 2022 13 463 M - -
P/E ratio 2022 38,1x
Yield 2022 1,54%
Capitalization 70 676 M 70 676 M -
EV / Sales 2022 4,51x
EV / Sales 2023 4,26x
Nbr of Employees 75 000
Free-Float 77,5%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 247,93 $
Average target price 277,58 $
Spread / Average Target 12,0%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Elizabeth McCombs Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY0.88%70 676
ABBOTT LABORATORIES-22.34%191 378
MEDTRONIC PLC-12.53%120 235
BAXTER INTERNATIONAL INC.-23.82%32 926
HOYA CORPORATION-31.18%31 359
DEXCOM, INC.-41.55%30 796